Association between the prevalence of antibodies to β2-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications

Clinical Chemistry

Volumn 47, Issue 6 I, 2001, Pages 1008-1015

  Nojima, J ^a   Kuratsune, H ^a   Suehisa, E ^a   Futsukaichi, Y ^a   Yamanishi, H ^a   Machii, T ^a   Iwatani, Y ^a   Kanakura, Y ^a  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; LIPOCORTIN 5; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; PLASMA PROTEIN; POLYSTYRENE; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ANTIGEN SPECIFICITY; ARTERY THROMBOSIS; ARTICLE; CHILD; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS WASTAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROTEIN IMMOBILIZATION; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

EID: 0035001425     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.6.1008     Document Type: Article

References (45)

1. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies
2. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein-I than with antiphospholipid antibodies
3. Increased levels of β2 glycoprotein-I antigen and β2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome
4. The antiphospholipid syndrome: Ten years on
5. Antiphospholipid antibodies: Predictive value of laboratory tests
6. Antiphospholipid antibodies and venous thromboembolism
7. The management of thrombosis in the antiphospholipid-antibody syndrome
8. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry
9. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy
10. Platelet activating properties of murine monoclonal antibodies to β2-glycoprotein I
11. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation
12. β2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulants
13. Platelets and antiphospholipid antibodies
14. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies
15. Stimulation of von Willebrand factor antigen release by immuno globulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome
16. Antiphospholipid antibodies directed against a combination of with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?
17. Inhibition of prostacyclin release by endothelial binding anticardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and the antiphospholipid syndrome
18. Pathogenesis of the antiphospholipid antibody syndrome
19. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis
20. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
21. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant
22. High prevalence of thrombocytopenia in SLE patients with a high level of anticardiolipin antibodies combined with lupus anticoagulant
23. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus-possible association with thrombotic and thrombocytopenic complications
24. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
25. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
26. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H)
27. β2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin
28. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor
29. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface
30. Reactivity to β2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis
31. Human β2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system
32. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin
33. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid
34. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies
35. "Anticardiolipin" autoantibodies recognize β2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding
36. Relationship of lupus anticoagulant, anticardiolipin, anti-β2-GPI and anti-prothrombin autoantibodies with history of thrombosis in patients with the clinical suspicion of APA-syndrome
37. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and β2-glycoprotein I-dependent antiphospholipid antibodies
38. Differential effects of anti-β2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C
39. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies
40. Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome
41. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies
42. Relationship of anti β2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies
43. Anti β2 glycoprotein I antibodies: Detection and association with thrombosis
44. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men-a nested case-control study
45. Antiphospholipid antibodies and thrombosis